{"id":5103,"date":"2019-07-15T15:40:52","date_gmt":"2019-07-15T13:40:52","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2020\/10\/08\/dynamic42-gmbh-raises-first-seed-round\/"},"modified":"2020-11-05T12:35:25","modified_gmt":"2020-11-05T11:35:25","slug":"dynamic42-gmbh-raises-first-seed-round","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2019-en\/dynamic42-gmbh-raises-first-seed-round\/","title":{"rendered":"Dynamic42 GmbH Raises First Seed Round"},"content":{"rendered":"
\n
Dynamic42 GmbH<\/a> has suc\u00adcess\u00adfully com\u00adpleted a six-fig\u00adure fundrais\u00ading in early sum\u00admer 2019 as an impor\u00adtant step towards future growth. The new invest\u00adment round will enable Dynamic42 to fur\u00adther its prod\u00aduct devel\u00adop\u00adment and mar\u00adket expan\u00adsion. bm|t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh (bm|t) made the invest\u00adment through its Th\u00fcringer Start-up Fund (TSF). Dr. Knut Ren\u00adnert and Mar\u00adtin Raasch, man\u00adag\u00ading direc\u00adtors at Dynamic42, agree \u201cthe invest\u00adment will sig\u00adnif\u00adi\u00adcantly scale up our oper\u00ada\u00adtions and open new busi\u00adness oppor\u00adtu\u00adni\u00adties. We are pleased to have bm|t on board as a strong part\u00adner at our side. We highly appre\u00adci\u00adate the sup\u00adport and trust bm\u2011t has given us.\u201d Dynamic42, based in Jena, was founded in 2018 and devel\u00adops microflu\u00adidic chip sys\u00adtems to cul\u00adti\u00advate human cells mim\u00adic\u00adk\u00ading real\u00adis\u00adtic body con\u00addi\u00adtions. \u201cOur sys\u00adtems uniquely incor\u00adpo\u00adrate adjust\u00adments for body tem\u00adper\u00ada\u00adture and nutri\u00adent sup\u00adply, which has been used in cyto\u00adlog\u00adi\u00adcal research over a long time. Our sys\u00adtems also offer the pos\u00adsi\u00adbil\u00adity to expose human cells to pres\u00adsure and shear\u00ading through sim\u00adu\u00adlated blood flow. Addi\u00adtion\u00adally, our sys\u00adtem is able to inte\u00adgrate a three-dimen\u00adsional cell struc\u00adture with immune cells into the chip. Both com\u00adpo\u00adnents imi\u00adtate the multi-cell struc\u00adture of the human body sig\u00adnif\u00adi\u00adcantly bet\u00adter than exist\u00ading mod\u00adels and pro\u00advide a real\u00adis\u00adtic sim\u00adu\u00adla\u00adtion of cell func\u00adtions and inter\u00adac\u00adtions\u201d, explains Mar\u00adtin Raasch. The team has suc\u00adcess\u00adfully estab\u00adlished organ mod\u00adels of the human liver, intestines and lung. \u201c<\/span>We started with the idea to rebuild and cul\u00adti\u00advate sim\u00adple blood ves\u00adsels under real\u00adis\u00adtic body con\u00addi\u00adtions. Those com\u00adpo\u00adnents remain an inte\u00adgral part of our mod\u00adels as they enable the inter\u00adcon\u00adnec\u00adtion of organs and func\u00adtion as impor\u00adtant trans\u00admit\u00adters in case of dis\u00adeases (esp. rel\u00ade\u00advant for immune cells). As we moved to the repli\u00adca\u00adtion of entire organ mod\u00adels, such as the liver, our project gained com\u00adplex\u00adity. The liver is one of the most crit\u00adi\u00adcal organs for drug inter\u00adac\u00adtions. Gen\u00aderal effects, side effects and poten\u00adtial tox\u00adi\u00adc\u00adity of new drugs and ther\u00ada\u00adpies are bet\u00adter inves\u00adti\u00adgated on real\u00adis\u00adtic human cell mod\u00adels than on two-dimen\u00adsional cell cul\u00adtures and ani\u00admal mod\u00adels only. Our goal is to improve drug safety and data qual\u00adity in pre\u00adclin\u00adi\u00adcal stud\u00adies, as well as to reduce side effects and the need for ani\u00admal exper\u00adi\u00adments\u201d, said Dr. Knut Ren\u00adnert. \u201cThe anatom\u00adi\u00adcally cor\u00adrect place\u00adment of human cells and the inte\u00adgra\u00adtion of func\u00adtional immune cells espe\u00adcially in con\u00adnec\u00adtion with a web-based clas\u00adsi\u00adfi\u00adca\u00adtion of vital\u00adity and func\u00adtion\u00adal\u00adity para\u00adme\u00adters offer high value to clients and large poten\u00adtial to gain addi\u00adtional mar\u00adket share in the rapidly grow\u00ading organ-on-chip mar\u00adket\u201d, stated Ste\u00adfan Jahn, invest\u00adment man\u00adager at bm|t.<\/div>\n

About bm|t<\/strong><\/h3>\n
bm|t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen GmbH is a fully-owned sub\u00adsidiary of Th\u00fcringer Auf\u00adbaubank based in Erfurt, Ger\u00admany. It is the lead\u00ading address for ven\u00adture cap\u00adi\u00adtal and pri\u00advate equity invest\u00adments in Thuringia. bm|t cur\u00adrently man\u00adages 8 funds with a total vol\u00adume of EUR 320mm. It invests in inno\u00adv\u00ada\u00adtive firms in nearly all sec\u00adtors and cor\u00adpo\u00adrate devel\u00adop\u00adment stages \u2013 from seed to growth phase and busi\u00adness suc\u00adces\u00adsions. (www.bm\u2011t.com<\/a>)<\/div>\n

About Dynamic42 GmbH<\/strong><\/h3>\n
Dynamic42 GmbH was founded in 2018 as a spin-off of the Cen\u00adter for Sep\u00adsis Con\u00adtrol and Care (CSCC) from the uni\u00adver\u00adsity clinic in Jena. Dynamic42 devel\u00adops and dis\u00adtrib\u00adutes humane micro phys\u00adi\u00ado\u00adlog\u00adi\u00adcal sys\u00adtems (MPS) and organ-on-chip mod\u00adels with inte\u00adgrated immune sys\u00adtem com\u00adpo\u00adnents for research and test\u00ading of phar\u00adma\u00adceu\u00adti\u00adcal prod\u00aducts as well as new ther\u00ada\u00adpies with nanopar\u00adti\u00adcles, chem\u00adi\u00adcals and food addi\u00adtives. (www.dynamic42.com<\/a>)<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Dynamic42 GmbH has suc\u00adcess\u00adfully com\u00adpleted a six-fig\u00adure fundrais\u00ading in early sum\u00admer 2019 as an impor\u00adtant step towards future growth. The new invest\u00adment round will enable Dynamic42 to fur\u00adther its prod\u00aduct devel\u00adop\u00adment and mar\u00adket expan\u00adsion. bm|t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh (bm|t) made the invest\u00adment through its Th\u00fcringer Start-up Fund (TSF). Dr. Knut Ren\u00adnert and Mar\u00adtin Raasch, managing [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[148],"tags":[177,168,170],"class_list":["post-5103","post","type-post","status-publish","format-standard","hentry","category-2019-en","tag-bmt-en","tag-startup-fonds-en","tag-tsf-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/5103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=5103"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/5103\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=5103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=5103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=5103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}